{"id":"W2903308035","doi":"10.1016/s0140-6736(18)32984-2","title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":726,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Brentuximab vedotin; Medicine; Chemotherapy; Oncology; Internal medicine; Lymphoma; Peripheral; CD30; Peripheral T-cell lymphoma; Double blind; Phases of clinical research; Immunology; Pathology; T cell; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03926279559710762,"score_gpt":0.3382484745491339,"score_spread":0.2989856789520263,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}